Patents by Inventor Pablo D. T. Valenzuela

Pablo D. T. Valenzuela has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7056658
    Abstract: Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A)x?(B)y?C2 which represents a linear amino acid sequence, wherein B is an amino acid sequence of an epitope or cluster of epitopes and each B contains at least five and not more than 1,000 amino acids, y is an integer of 2 or more, A and C are each independently an amino acid sequence of an epitope or cluster of epitopes not adjacent to B in nature and x and z are each independently an integer of 0 or more wherein at least one of x and z is 1 or more.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: June 6, 2006
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, David Ying Chien
  • Patent number: 6844168
    Abstract: A new receptor for fibroblast growth factor has been cloned and expressed. The recombinant receptor is useful for inhibiting FGF activity, and for screening compounds for binding activity similar to that of FGF. A soluble, truncated recombinant receptor is also prepared, and is capable of binding FGF.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: January 18, 2005
    Assignee: Chiron Corporation
    Inventors: Michael C. Keifer, Pablo D. T. Valenzuela, Philip J. Barr
  • Patent number: 6642029
    Abstract: Methods and compositions are provided for efficient production of human insulin-like growth factor. Synthetic IGF I and IGF II genes are joined to leader and processing signals which provide for expression and secretion of the gene product in yeast. Enhanced yields of the product may then be recovered from the nutrient medium. Yeast strains S. cerevisiae AB103 (pYIGF-I-10/1) and AB103 (pYIGF-II-10/1) were deposited at the American Type Culture Collection on Apr. 23, 1983 and granted Accession Nos. 20673 and 20674, respectively.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: November 4, 2003
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, Guy Mullenbach
  • Patent number: 6544757
    Abstract: The present invention relates to synthesis of HBSAg in yeast. Yeast expression vectors comprising a yeast promoter, ADH1, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector. Using the described yeast vector, the successful synthesis of HBSAg by yeast has been achieved. The product is antigenic (reactive with anti-HBSAg), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBSAg synthesized by yeast has identical sedimentation behavior to purified, naturally occurring HBSAg particles purified from Alexander cells as measured by sucrose gradient sedimentation.
    Type: Grant
    Filed: June 21, 1988
    Date of Patent: April 8, 2003
    Assignee: The Regents of the University of California
    Inventors: William J. Rutter, Pablo D. T. Valenzuela, Benjamin D. Hall, Gustav Ammerer
  • Publication number: 20030044774
    Abstract: Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A)x-(B)y-Cz which represents a linear amino acid sequence, wherein B is an amino acid sequence of an epitope or cluster of epitopes and each B contains at least five and not more than 1,000 amino acids, y is an integer of 2 or more, A and C are each independently an amino acid sequence of an epitope or cluster of epitopes not adjacent to B in nature and x and z are each independently an integer of 0 or more wherein at least one of x and z is 1 or more.
    Type: Application
    Filed: June 17, 2002
    Publication date: March 6, 2003
    Applicant: Chiron Corporation
    Inventors: Pablo D.T. Valenzuela, David Ying Chien
  • Patent number: 6514731
    Abstract: Human hepatitis C virus (HCV) has been identified as the aetiological agent of non-A, non-B hepatitis (NANBH). HCV viruses display considerable genotypic and phenotypic heterogeneity. Thus, there is considerable need in the art for more sensitive reagents that facilitate the detection of HCV variants. The genome of hepatitis C virus (HCV) consists of seven functional regions: the core, E1, E2/NS1, NS2, NS3, NS4, and NS5 regions. An attempt was made to improve the sensitivity of anti-HCV assays by developing multiple copy epitope fusion antigens (MEFAs) which incorporate the major immunodominant epitopes from the functional regions of the HCV genome. These MEFAs are encompassed by the following generic structural formula: (A)x—(B)y—(C)z. This formula represents a linear amino acid sequence comprising multiple copies of one HCV epitope (A) linked to multiple copies of another HCV epitope (B) which in turn is linked to multiple copies of yet another HCV epitope (C).
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: February 4, 2003
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, David Ying Chien
  • Patent number: 6475489
    Abstract: The present invention relates to synthesis of HBsAg in yeast. Yeast expression vectors comprising a yeast promoter, ADH1, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector. Using the described yeast vector, the successful synthesis of HBsAg by yeast has been achieved. The product is antigenic (reactive with anti-HBsAg), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBSAg synthesized by yeast has identical sedimentation behavior to purified, naturally-occurring HBsAq particles purified from Alexander cells as measured by sucrose gradient sedimentation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 5, 2002
    Assignee: The Regents of the University of California
    Inventors: William J. Rutter, Pablo D. T. Valenzuela, Benjamin D. Hall, Gustav Ammerer
  • Patent number: 6428792
    Abstract: Human hepatitis C virus (HCV) has been identified as the aetiological agent of non-A, non-B hepatitis (NANBH). HCV viruses display considerable genotypic and phenotypic heterogeneity. Thus, there is considerable need in the art for more sensitive reagents that facilitate the detection of HCV variants. The genome of hepatitis C virus (HCV) consists of seven functional regions: the core, E1, E2/NS1, NS2, NS3, NS4, and NS5 regions. An attempt was made to improve the sensitivity of anti-HCV assays by developing multiple copy epitope fusion antigens (MEFAs) which incorporate the major immunodominant epitopes from the functional regions of the HCV genome. These MEFAs are encompassed by the following generic structural formula: (A)x—(B)y—(C)z. This formula represents a linear amino acid sequence comprising multiple copies of one HCV epitope (A) linked to multiple copies of another HCV epitope (B) which in turn is linked to multiple copies of yet another HCV epitope (C).
    Type: Grant
    Filed: May 20, 1997
    Date of Patent: August 6, 2002
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, David Ying Chien
  • Patent number: 6255454
    Abstract: A new receptor for fibroblast growth factor has been cloned and expressed. The recombinant receptor is useful for inhibiting FGF activity, and for screening compounds for binding activity similar to that of FGF. A soluble, truncated recombinant receptor is also prepared, and is capable of binding FGF.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: July 3, 2001
    Assignee: Chiron Corporation
    Inventors: Michael C. Keifer, Pablo D. T. Valenzuela, Philip J. Barr
  • Patent number: 5965140
    Abstract: Novel immunogenic compositions are provided involving viral particles composed at least in part of hybrid proteins of at least a portion of a particle forming protein and one or more polypeptides having at least one epitope of interest. Nucleic acid sequences are employed coding for the hybrid protein which are introduced into a host cell for expression, either by themselves or in combination with other DNA sequences coding for particle forming proteins. Expression of the DNA sequences results in formation of particles which may be isolated and used as immunogens for production of antibodies for diagnostics purposes, passive immunization, vaccination, or other uses.Saccharomyces carlsbergensis, 2150-2-3 (pDC103), was deposited on Sep. 7, 1984, at the ATCC and given ATCC Accession No. 20726. Also, Saccharomyces cerevisiae PO17 (pCl/l-MCS29) was deposited at the ATCC on Sep. 5, 1985, and given ATCC Accession No. 20770.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: October 12, 1999
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, George Kuo, Philip J. Barr
  • Patent number: 5792463
    Abstract: Novel immunogenic compositions are provided involving viral particles composed at least in part of hybrid proteins of at least a portion of a particle forming protein and one or more polypeptides having at least one epitope of interest. Nucleic acid sequences are employed coding for the hybrid protein which are introduced into a host cell for expression, either by themselves or in combination with other DNA sequences coding for particle forming proteins. Expression of the DNA sequences results in formation of particles which may be isolated and used as immunogens for production of antibodies for diagnostics purposes, passive immunization, vaccination, or other uses.Saccharomyces carlsbergensis, 2150-2-3 (pDC103), was deposited on Sep. 7, 1984, at the ATCC and given ATCC Accession No. 20726. Also, Saccharomyces cerevisiae PO17 (pC1/1-MCS29) was deposited at the ATCC on Sep. 5, 1985, and given ATCC Accession No. 20770.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: August 11, 1998
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, George Kuo, Philip J. Barr
  • Patent number: 5759814
    Abstract: The glycoprotein B ("gB") and analogs thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and analogous proteins as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 2, 1998
    Assignee: Chiron Corporation
    Inventors: Rae L. Burke, Carol Pachl, Pablo D.T. Valenzuela
  • Patent number: 5750114
    Abstract: Vaccines and therapeutic compositions and methods for their production and use against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D. The following E. coli HB101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain; pHS203; pHS112; pHS114; pHS127A and pHS206 were deposited on Apr. 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on Jul. 11, 1984, and given Accession Nos. 39762 and 39763, respectively.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: May 12, 1998
    Assignee: Chiron Corporation
    Inventors: Rae Lyn Burke, Carol Pachl, Pablo D. T. Valenzuela
  • Patent number: 5747039
    Abstract: Vaccines and therapeutic compositions and methods for their production and use against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D.The following E. coli HB101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain; pHS203; pHS112; pHS114; pHS127A and pHS206 were deposited on Apr. 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on Jul. 11, 1984, and given Accession Nos. 39762 and 39763, respectively.
    Type: Grant
    Filed: February 8, 1995
    Date of Patent: May 5, 1998
    Assignee: Chiron Corporation
    Inventors: Rae Lyn Burke, Carol Pachl, Pablo D. T. Valenzuela
  • Patent number: 5733851
    Abstract: Methods and compositions for treating the root system of seedlings, young plants, and plants at whatever stage of development. Examples of the plants to be treated includes forestry species, horticultural species, floricultural species, and other important agricultural crops. Such treatment enhances plant resistance to pests and survival in adverse environmental conditions. The results include significant overall improvements in growth and yield of said forestry, horticultural, and other crops.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: March 31, 1998
    Inventors: Jaime Villanueva, Pablo D.T. Valenzuela
  • Patent number: 5648079
    Abstract: The glycoprotein B ("gB") and analogs thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and analogous proteins as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: July 15, 1997
    Assignee: Chiron Corporation
    Inventors: Rae L. Burke, Carol Pachl, Pablo D. T. Valenzuela
  • Patent number: 5612041
    Abstract: Vaccines against Herpes Simplex virus containing recombinant polypeptides which are cross-reactive with glycoprotein D of the virus, methods for their production using recombinant DNA techniques in yeast, and methods for the use of the vaccine are provided. E. coli strains HB101 containing plasmids pYHS 109 and pYHS118 were deposited at the American Type Culture Collection on Jul. 11, 1984, and granted accession nos. 39762 and 39763, respectively.
    Type: Grant
    Filed: September 27, 1994
    Date of Patent: March 18, 1997
    Assignee: Chiron Corporation
    Inventors: Rae L. Burke, Mickey S. Urdea, Pablo D. T. Valenzuela
  • Patent number: 5244792
    Abstract: The glycoprotein B ("gB") and functional fragments thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and functional fragments thereof as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines. The following E. coli HB101 strains were deposited at the A.T.C.C. on April 4, 1984, where the plasmid indicates the plasmid employed to transform the strain; pHS112; pHS114 (gB1 mammalian); pHS127A (gB1 yeast); pHS203; and pHS206 (gB2), and assigned Accession Nos. 39649-39653, respectively, where the nature of the plasmid is indicated in parentheses and the number refers back to the number employed in the Experimental section.
    Type: Grant
    Filed: September 20, 1990
    Date of Patent: September 14, 1993
    Assignee: Chiron Corporation
    Inventors: Rae L. Burke, Carol Pachl, Pablo D. T. Valenzuela
  • Patent number: 5229501
    Abstract: A new receptor for fibroblast growth factor has been cloned and expressed. The recombinant receptor is useful for inhibiting FGF activity, and for screening compounds for binding activity similar to that of FGF. A soluble, truncated recombinant receptor is also prepared, and is capable of binding FGF.
    Type: Grant
    Filed: January 11, 1991
    Date of Patent: July 20, 1993
    Assignee: Chiron Corporation
    Inventors: Michael C. Keifer, Pablo D. T. Valenzuela, Philip J. Barr
  • Patent number: 5171568
    Abstract: Vaccines and therapeutic compositions and methods for their production and use against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D.The following E. coli HB 101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain; pH203; pHS112; pHS114; pHS127A and pHS206 were deposited on Apr. 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on Jul. 11, 1984, and given Accession Nos. 39762 and 39763, respectively.
    Type: Grant
    Filed: October 2, 1989
    Date of Patent: December 15, 1992
    Assignee: Chiron Corporation
    Inventors: Rae L. Burke, Carol Pachl, Pablo D. T. Valenzuela